Preventing and treating cardiovascular disease (Lipid Series - Part 3) | Dr Thomas Dayspring | The Proof with Simon Hill

This podcast episode underscores the ethical considerations surrounding ketogenic diets and their potential impact on cardiovascular health, particularly regarding ApoB levels, a critical marker for atherosclerotic cardiovascular disease. Dr. Thomas Dayspring leads an insightful discussion on the significance of both lifestyle and pharmacotherapy in managing lipid levels, delving into various lipid-lowering interventions—from statins and PCSK9 inhibitors to emerging gene therapies. The dialogue emphasizes the limitations of solely focusing on HDL and triglycerides, advocating for a more comprehensive lipid management strategy that prioritizes ApoB levels to effectively reduce cardiovascular risk.

Outlines

Sign in to continue reading, translating and more.

Continue

Preventing and treating cardiovascular disease (Lipid Series - Part 3) | Dr Thomas Dayspring

The Proof with Simon Hill

The Ethics of Ketogenic Diets and Atherosclerotic Cardiovascular Disease

A Historical Perspective on Cardiovascular Disease Mortality Reduction

The Role of Lifestyle vs. Pharmacotherapy in Cardiovascular Health

Understanding ApoB and the Mechanisms of Lipid-Lowering Drugs

Bile Acid Sequestrants: The First Drug to Show Cardiovascular Outcome Benefit

Statins: A Game-Changer in Cardiovascular Disease Prevention

Statin Side Effects, Pleiotropic Effects, and the Importance of Desmosterol Monitoring

Ezetimibe and Bempedoic Acid: Alternatives to Statins with Less Impact on Brain Cholesterol Synthesis

PCSK9 Inhibitors: The Most Potent ApoB-Lowering Drugs

Why Statins Remain the Drug of Choice for Lipid Management

Gene Therapy and CRISPR for PCSK9: A Promising Future for Cardiovascular Disease Prevention

The Myths of "Good" and "Bad" Cholesterol and the Limitations of HDL-Raising Drugs

Understanding Low HDL Cholesterol and its Relationship to ApoB

The Role of HDL in Reverse Cholesterol Transport and the Importance of ApoB Management

The Impact of Elevated Triglycerides on Lipid Metabolism and Cardiovascular Disease

Fibrates, Omega-3 Fatty Acids, and the Importance of Targeting ApoB

The Importance of Targeting ApoB and the Limitations of Focusing Solely on Triglycerides and HDL

Key Takeaways and Target Levels for ApoB Management

Preventing and treating cardiovascular disease (Lipid Series - Part 3) | Dr Thomas Dayspring

The Proof with Simon Hill

00:00The Ethics of Ketogenic Diets and Atherosclerotic Cardiovascular Disease

The Ethics of Ketogenic Diets and Atherosclerotic Cardiovascular Disease

03:06A Historical Perspective on Cardiovascular Disease Mortality Reduction

A Historical Perspective on Cardiovascular Disease Mortality Reduction

09:41The Role of Lifestyle vs. Pharmacotherapy in Cardiovascular Health

The Role of Lifestyle vs. Pharmacotherapy in Cardiovascular Health

12:02Understanding ApoB and the Mechanisms of Lipid-Lowering Drugs

Understanding ApoB and the Mechanisms of Lipid-Lowering Drugs

15:18Bile Acid Sequestrants: The First Drug to Show Cardiovascular Outcome Benefit

Bile Acid Sequestrants: The First Drug to Show Cardiovascular Outcome Benefit

18:02Statins: A Game-Changer in Cardiovascular Disease Prevention

Statins: A Game-Changer in Cardiovascular Disease Prevention

28:25Statin Side Effects, Pleiotropic Effects, and the Importance of Desmosterol Monitoring

Statin Side Effects, Pleiotropic Effects, and the Importance of Desmosterol Monitoring

40:54Ezetimibe and Bempedoic Acid: Alternatives to Statins with Less Impact on Brain Cholesterol Synthesis

Ezetimibe and Bempedoic Acid: Alternatives to Statins with Less Impact on Brain Cholesterol Synthesis

59:21PCSK9 Inhibitors: The Most Potent ApoB-Lowering Drugs

PCSK9 Inhibitors: The Most Potent ApoB-Lowering Drugs

1:16:40Why Statins Remain the Drug of Choice for Lipid Management

Why Statins Remain the Drug of Choice for Lipid Management

1:22:34Gene Therapy and CRISPR for PCSK9: A Promising Future for Cardiovascular Disease Prevention

Gene Therapy and CRISPR for PCSK9: A Promising Future for Cardiovascular Disease Prevention

1:29:51The Myths of "Good" and "Bad" Cholesterol and the Limitations of HDL-Raising Drugs

The Myths of "Good" and "Bad" Cholesterol and the Limitations of HDL-Raising Drugs

1:37:03Understanding Low HDL Cholesterol and its Relationship to ApoB

Understanding Low HDL Cholesterol and its Relationship to ApoB

1:40:33The Role of HDL in Reverse Cholesterol Transport and the Importance of ApoB Management

The Role of HDL in Reverse Cholesterol Transport and the Importance of ApoB Management

1:50:08The Impact of Elevated Triglycerides on Lipid Metabolism and Cardiovascular Disease

The Impact of Elevated Triglycerides on Lipid Metabolism and Cardiovascular Disease

1:58:54Fibrates, Omega-3 Fatty Acids, and the Importance of Targeting ApoB

Fibrates, Omega-3 Fatty Acids, and the Importance of Targeting ApoB

2:04:39The Importance of Targeting ApoB and the Limitations of Focusing Solely on Triglycerides and HDL

The Importance of Targeting ApoB and the Limitations of Focusing Solely on Triglycerides and HDL

2:08:17Key Takeaways and Target Levels for ApoB Management

Key Takeaways and Target Levels for ApoB Management